Context Therapeutics Inc (NASDAQ:CNTX)’s traded shares stood at 2.41 million during the last session, with the company’s beta value hitting 2.27. At the close of trading, the stock’s price was $2.23, to imply an increase of 11.50% or $0.23 in intraday trading. The CNTX share’s 52-week high remains $2.75, putting it -23.32% down since that peak but still an impressive 65.47% since price per share fell to its 52-week low of $0.77. The company has a valuation of $167.25M, with an average of 0.35 million shares in intraday trading volume over the past 10 days and average of 182.18K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Context Therapeutics Inc (CNTX), translating to a mean rating of 1.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give CNTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Context Therapeutics Inc (NASDAQ:CNTX) trade information
After registering a 11.50% upside in the last session, Context Therapeutics Inc (CNTX) has traded red over the past five days. The 5-day price performance for the stock is 8.78%, and 13.78% over 30 days. With these gigs, the year-to-date price performance is 97.35%. Short interest in Context Therapeutics Inc (NASDAQ:CNTX) saw shorts transact 1.09 million shares and set a 3.89 days time to cover.
The extremes give us $4.5 and $6 for target low and target high price respectively. As such, CNTX has been trading -169.06% off suggested target high and -101.79% from its likely low.
Context Therapeutics Inc (CNTX) estimates and forecasts
Looking at statistics comparing Context Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Context Therapeutics Inc (CNTX) shares are 71.54% up over the last 6 months, with its year-to-date growth rate higher than industry average at 73.33% against 17.50%.
CNTX Dividends
Context Therapeutics Inc has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Context Therapeutics Inc (NASDAQ:CNTX)’s Major holders
Context Therapeutics Inc insiders hold 1.45% of total outstanding shares, with institutional holders owning 76.40% of the shares at 77.52% float percentage. In total, 76.40% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 4.5 million shares (or 28.1986% of shares), all amounting to roughly $9.03 million.
The next major institution holding the largest number of shares is GREAT POINT PARTNERS LLC with 7.42 million shares, or about 13.4999% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $14.88 million.
